The American pharmaceutical company Pfizer, thanks again to a savings program with billions of profit, announced another purchase: Pfizer has exercised a call option to acquire US-based pharmaceutical company Nextwave – worth $255 million.
The purchase price also includes sales-related milestone targets which could amount to a further $425 million being paid. In the second quarter of 2012, Pfizer acquired the option to acquire the pharmaceutical company for $20 million.
NextWave provides the medication XR Quillivant for the treatment of attention-deficit/hyperactivity disorder (ADHD). The company has the exclusive marketing rights for the drug in North America, which will probably be discussed in January 2013 in the trade.
[ilink url=“http://salesandmarketingnetwork.com/news_release.php?ID=2035877″] Link zur Quelle (Healthcare Sales & Marketing)[/ilink]